"Purple Crack" - The Globe magazine had an interesting story this week about Prilosec in specific and drug companies in general. This business is a bit of a mystery to me, especially the rules surrounding patents vs. generics. The article contends that AstraZeneca is using its lawyers to extend the profitable life of Prilosec (preventing cheaper generics) while readying a switch to a new drug (Nexium) that doesn't really work any better but has a new patent.
Boston Globe Online / Magazine